Fiche publication
Date publication
mai 2021
Journal
Rheumatology (Oxford, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GOTTENBERG Jacques-Eric
,
Pr MARTIN Thierry
,
Pr GENY Bernard
Tous les auteurs :
Levy D, Nespola B, Giannini M, Felten R, Severac F, Varoquier C, Rinagel M, Korganow AS, Martin T, Poindron V, Maurier F, Chereih H, Bouldoires B, Hervier B, Lenormand C, Chatelus E, Geny B, Sibilia J, Arnaud L, Gottenberg JE, Meyer A
Lien Pubmed
Résumé
We recently recorded a high prevalence of inclusion body myositis (IBM) in patients with Sjögren's syndrome (SS). Whether myositis patients with SS differ from myositis patients without SS in terms of the characteristics of the myositis is currently unknown. Anti-cytosolic 5'-nucleotidase 1 A (cN1A) has recently been proposed as a biomarker for IBM but is also frequent in SS. Whether anti-cN1A is independently associated with IBM is still an open question. We aimed to assess the significance of SS and anti-cN1A in myositis patients.
Mots clés
Myositis, Sjögren’s syndrome, anti-cN1A, anti-synthetase syndrome, dermatomyositis, inclusion body myositis, inflammatory myopathies, polymyositis
Référence
Rheumatology (Oxford). 2021 May 11;:
